.png){kind=icon}
.png){kind=icon}
Return
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
.png){kind=icon}
PRE
AI
X
C
Z
J
Y
T
Y
W
X
Z
B
Y
X
Q
DOI：10.1038/s41591-026-04564-7.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Triple-negative breast cancer is an aggressive subtype comprising 10–20% of all breast cancer cases and has a worse prognosis than other subtypes. This open-label, multicenter, single-arm, phase 2 clinical trial evaluates the safety and efficacy of ivonescimab combined with chemotherapy as first-line treatment in female patients with locally advanced unresectable or metastatic triple-negative breast cancer who have not received previous systemic therapy. Eligible patients received ivonescimab 20 mg kg−1 intravenously every 2 weeks and paclitaxel 90 mg m−2 or nab-paclitaxel 100 mg m−2 intravenously on days 1, 8 and 15 of each 4-week treatment cycle. The primary endpoints were safety and the investigator-assessed objective response rate per RECIST v.1.1. A total of 36 patients were enrolled. As of July 15, 2025, the median follow-up duration was 22.1 months. The primary endpoints were met. Treatment-related adverse events occurred in 36 (100.0%) patients. Grade ≥3 treatment-related adverse events were reported in 21 (58.3%) patients. No treatment-related deaths occurred. Immune-related adverse events occurred in 15 (41.7%) patients, with grade ≥3 events in 4 (11.1%) patients. Of the 35 patients evaluable for treatment efficacy, the objective response rate was 80.0% (95% confidence interval: 63.1–91.6), including 2 (5.7%) complete responses and 26 (74.3%) partial responses. Ivonescimab plus chemotherapy demonstrated encouraging antitumor activity as first-line therapy for patients with previously untreated advanced triple-negative breast cancer and merits further investigation. ClinicalTrials.gov identifier:
NCT05227664
. In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates, which support further testing in a large, randomized, phase 3 trial.
Journal
IF:
50
Papers:
1.4W
Citations:
13.4W
Organization
Cited Papers